David Steensma on Twitter

from twitter post

And the reason I was there at #EHA23 - #imetelstat MDS phase 2. We saw 34% >=8 week transfusion independence and 5/32 pts with 24+ week RBC free in IPSS lower risk ESA-refractory/relapsed/ineligible patients with high transfusion burden (>=4U RBCs in 8 weeks prior to screening)

post 2
In the interest of a balanced tweet summarizing a presentation: AEs included neutropenia and thrombocytopenia in most patients, 1 episode febrile neutropenia, headache in 25% and transamimase elevation in 19%.

post 3
I’d have to defer to the sponsor on that. Clearly it is an active agent and 22 additional patients have now been accrued in a cohort w/o prior treatment with HMA or lenalidomide, who will be reported at a later date, then a decision about when/how to proceed with next phase.

link